Enforcement Trends: OIG Calls Out CMS for Not Preventing Medicare Genetic Testing Overpayments
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.
Labs will have to submit Z-Codes with every molecular pathology testing code billed to UnitedHealthcare, starting Aug. 1.
Key approvals announced in June represented important steps forward for the lab testing industry.
The outlook of the global genetic testing market based on recent reports from five financial consulting firms.